Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03469804
Other study ID # P160601
Secondary ID 2016-003714-27
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 1, 2018
Est. completion date September 20, 2020

Study information

Verified date October 2019
Source Assistance Publique - Hôpitaux de Paris
Contact Celeste LEBBE, MD PhD
Phone 142499590
Email celeste.lebbe@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Classic and endemic Kaposi's sarcoma (KS) are lymphangio-proliferations associated with human herpes virus 8 (HHV8), which treatment is poorly codified. Chemotherapies give at best 30-60% of transient responses. While interferon responses are frequent, this drug is often poorly tolerated in elderly patients. Therefore new therapies are needed. Classic KS represents an ideal model for evaluating new drugs since patients do not receive concomitant immunosuppressive regimens nor antiviral therapies.

Pembrolizumab, an anti-PD1 monoclonal antibody has recently been shown to improve survival in several solid tumors. In KS few data are available on the role of PD1-PD-L1 axis. A significant PD-L1 expression on HHV8-associated pleural effusion lymphomas and on KS samples have been recently reported. Our experience in classical and endemic KS supports the role of this pathway with expression of PD-L1 by subpopulations of T cells but also NK cells in peripheral blood cells from these patients and expression of PD-L1 by tumor cells in KS lesions.

In this study we will evaluate the benefit and safety profile of pembrolizumab in classic and endemic KS.


Recruitment information / eligibility

Status Recruiting
Enrollment 17
Est. completion date September 20, 2020
Est. primary completion date March 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Classic or endemic histologically confirmed KS

- Progressive disease

- KS with more than 10 lesions or involving more than one limb segment or with involvement >3% body surface

- KS with at least 4 lesions =5mm

- KS with at least 1 other cutaneous tumor available for repeated pharmacodynamics evaluation and be willing to provide tissue from cutaneous biopsy of a tumor lesion

- At least 4 weeks washout for all KS specific therapies including chemotherapy and immunotherapy

- Provide written, informed consent prior to the performance of any study specific procedures

- Be = 18 years of age on day of signing informed consent.

- Have a performance status of 0 or 1 on the ECOG Performance Scale.

- Demonstrate adequate organ function:

Hematological : Absolute neutrophil count (ANC) =1,000/mm3, Platelets =100,000 / mm3, Hemoglobin = 9 g/dL Renal: Calculated creatinine clearance =40 mL/min (using Modification of diet in renal disease (MDRD) formula) Hepatic: AST (SGOT) and ALT (SGPT) = 2.5xULN, serum total bilirubin = 1.5xULN OR direct bilirubin = ULN for subjects with total bilirubin levels >1.5xULN.

- Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication

- Have a health insurance

Exclusion Criteria:

- Has a known history of organ transplantation or HIV (HIV 1/2 antibodies detected at selection) Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

- Has KS with symptomatic visceral involvement unless no other therapeutic option is available Previously received treatments with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 antibody or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.

- Has a known history of active infectious hepatitis, type B (HBsAg detected) or C (HCV RNA detected) or active TB (Tuberculosis Bacillus).

- Has an active infection requiring systemic therapy.

- Has hypersensitivity to pembrolizumab or any of its excipients.

- Has had a prior anti-cancer monoclonal antibody (mAb) within last 4 weeks or who has not recovered (i.e., > Grade 1 at selection) from adverse events due to agents administered more than 4 weeks earlier.

- Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 3 weeks prior to study Day 1 or who has not recovered (i.e., > Grade 1 at selection) from adverse events due to a previously administered agent (Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and may qualify for the study). (Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy).

- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.

- Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with vitiligo, type I diabetes mellitus, hypothyroidism, psoriasis non requiring systemic treatment are permitted to enroll.

- Has active non-infectious pneumonitis or known history of non-infectious pneumonitis that required steroids, severe pulmonary disease or hypoxia

- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, or not willing to use adequate contraceptive methods from study Visit 1 throughout the study period up to 120 days after the last dose of study therapy.

- Has received a live vaccine within 30 days prior to the first dose of trial treatment or while participating in the trial.

- Is currently participating or has participated in a study of an investigational agent within 4 weeks of the first dose of treatment.

- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

- Patient under guardianship or curators

Study Design


Intervention

Drug:
Pembrolizumab
Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)

Locations

Country Name City State
France Saint-Louis Hospital Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Best Overall Response Rate (BORR) Best Overall Response Rate (BORR) defined by the occurrence of complete response or partial response following AIDS Clinical Trials Group (ACTG) criteria recorded from the start of treatment until 6 months or the beginning of any other specific systemic therapy for KS if it occurs before 6 months 6 months
Secondary Best overall response rate according to Physical Global Assessment (PGA) Best overall response rate according to Physical Global Assessment (PGA) score until 6 months or the beginning of any other specific systemic therapy for KS if it occurs before 6 months 6 months
Secondary Response rate according to ACTG and PGA criteria 3 months
Secondary Response rate according to ACTG and PGA criteria 6 months
Secondary Response rate on number of lesions Response rate on number of lesions and at best response as defined following ACTG criteria 3 months
Secondary Response rate on number of lesions Response rate on number of lesions and at best response as defined following ACTG criteria 6 months
Secondary Response rate on the size of target lesions Response rate on the size of target lesions and at best response as defined following ACTG criteria 3 months
Secondary Response rate on the size of target lesions Response rate on the size of target lesions and at best response as defined following ACTG criteria 6 months
Secondary Response rate on tumor infiltration of target lesions Response rate on tumor infiltration of target lesions and at best response as defined following ACTG criteria 3 months
Secondary Response rate on tumor infiltration of target lesions Response rate on tumor infiltration of target lesions and at best response as defined following ACTG criteria 6 months
Secondary Response rate on lymphedema Response rate on lymphedema (circumference, scale of 0 (absence) to 3 (painful or oozing)) at Month 3, Month 6 and at best response as defined following ACTG criteria 3 months
Secondary Response rate on lymphedema Response rate on lymphedema (circumference, scale of 0 (absence) to 3 (painful or oozing)) at Month 3, Month 6 and at best response as defined following ACTG criteria 6 months
Secondary Time to response Time to response defined as the time to first response recorded from the start of treatment 6 months
Secondary Time to progression 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06445166 - Propranolol for the Treatment of Kaposi Sarcoma in Adults Phase 2
Recruiting NCT04941274 - Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma Phase 1/Phase 2
Completed NCT03160183 - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Recruiting NCT03993106 - A Study of sEphB4-HSA in Kaposi Sarcoma Phase 2
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Completed NCT00395278 - Development of Serologic Assays for Human Herpes Virus-8
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Completed NCT03296553 - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. Phase 2
Recruiting NCT04305691 - Trial of Ixazomib for Kaposi Sarcoma Phase 2
Completed NCT03316274 - Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma Early Phase 1
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Terminated NCT04893018 - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Phase 1
Recruiting NCT06375122 - Natural History Study of Kaposi Sarcoma
Recruiting NCT05663502 - Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Recruiting NCT05329792 - L19IL2/L19TNF in Skin Cancer Patients Phase 2
Not yet recruiting NCT05411237 - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Phase 3
Completed NCT03050788 - Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma N/A
Completed NCT03404297 - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya N/A
Terminated NCT01412515 - A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma Phase 2
Not yet recruiting NCT06004011 - AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) N/A